Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities'
Galapagos NV (NASDAQ:GLPG) stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing.
Galapagos NV （納斯達克：GLPG）股票週一交投上漲，因Ecor1 Capital在13D申報中報告了對該歐洲生物技術公司9.9%的持股。
EcoR1 Capital is now planning to talk to the Belgian biotech about its performance, business, operations, strategic opportunities, and governance, including Board composition.
EcoR1 Capital現在計劃與比利時生物技術公司討論其業績、業務、運營、戰略機遇和治理，包括董事會組成。
By June 2023, the biotech-focused investment fund had accumulated a 9.87% stake in the company.
到2023年6月，這家生物技術投資基金已經累積了公司9.87%的持股。
Also Read: Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst.
另請參閱：Galapagos股票遭到下調，生物製藥公司面臨緩慢管線進展的艱難戰鬥：分析師。
The SEC filing provides details of how EcoR1 views Galapagos and how it plans to use its stake to try to shape the direction of the biotech, with the investor stating that the company's shares are "deeply undervalued and represent an attractive investment opportunity."
SEC的文件詳細介紹了EcoR1是如何看待Galapagos的以及它計劃如何利用其持股來塑造該生物技術公司的發展方向，投資者表示公司股票「被嚴重低估並且代表着一個有吸引力的投資機會」。
Galapagos' share price has fallen more than 25% over the past year, but the stock has performed even worse over a longer period.
Galapagos的股價在過去一年中下跌了超過25%，但股票的表現在更長的時間段內甚至更糟。
Galapagos, once seen as one of Europe's leading drug innovators, has struggled in recent years due to R&D failures, regulatory challenges, and ineffective partnerships, Stat News noted.
Galapagos曾被視爲歐洲領先的藥物創新者之一，但由於研發失敗、監管挑戰和無效的合作伙伴關係，近年來一直備受掙扎，Stat News指出。
In 2022, Paul Stoffels, a renowned drug developer and former Johnson & Johnson executive, returned from a brief retirement to become the company's CEO.
在2022年，著名的藥物開發者、前強生公司高管Paul Stoffels先生從短暫的退休中返回，成爲該公司的首席執行官。
Stoffels vowed to revamp Galapagos' R&D, focusing on CAR-T cancer therapies, but the report adds that progress has been sluggish and underwhelming in Wall Street's eyes.
斯托菲爾斯承諾改革galapagos的研發工作，重點放在CAR-T抗癌療法上，但報告指出，在華爾街看來，進展緩慢，令人失望。
According to data from Benzinga Pro, the company's enterprise value is negative $2.1 billion, indicating that its cash reserves outweigh the value of its assets, including its drug pipeline.
根據Benzinga Pro的數據，該公司的企業價值爲負2100萬美元，表明其現金儲備超過了其資產價值，包括其藥物流水線。
Most recently, the FDA cleared Galapagos' Investigational New Drug application for ATALANTA-1 Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma.
最近，FDA批准了Galapagos的ATALANTA-1階段1/2多中心研究的新藥申請，評估GLPG5101在復發/難治性非霍奇金淋巴瘤患者中的可行性、安全性和療效。
Price Action: GLPG stock is up 10.4% at $28.59 at last check Monday.
價格走勢：GLPG股票最近檢查週一上漲10.4%，至28.59美元。
Illustration of Phrama lab worker created with MidJourney.
藥廠實驗室工作者插圖，由MidJourney創建。
- Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program.
- 美國人可以免費獲得COVID-19測試工具包，因爲美國政府重新啓動了免費在家使用的計劃。
